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Introduction: The neuroendocrine histamine-secreting cell ofthe gastric fundus,
the enterochromaffin-like cell, is the principal regulator of parietal cell acid
secretion. We have proposed that histamine may regulate its own synthesis and
release via an autocrine mechanism. The purpose of this study was to evaluate
the role of the histamine receptor subtypes H1, H2 and H3 in the regulation of
this phenomenon.
Methods: Purified ECL cells were isolated by pronase digestion and EDTA
exposure of the rat stomach, followed by particle size and density separation
using counterflow elutriation and Nycodenz gradient centrifugation. 24-hr cul-
tured cells were pretreated for 30 min with the agents; H1 receptor agonist (2-
[(3-trimethyl)-diphenyl] histamine) (TMPH), H, receptor antagonist (terfena-
dine); H2 receptor agonist (dimaprit) or antagonist (cimetidine or loxtidine); or
H3 receptor agonist (imetit) or antagonist (thioperamide) (all tested, 10-10O_1-6
M). Gastrin was then used to stimulate histamine secretion. Histamine secretion
was quantified by specific enzyme-immunoassay.
Results: Basal histamine secretion was 2.7 + 0.14 nmol/103 cells. Gastrin-stim-
ulated (10 nM) levels were 4.6 + 0.4 nmol/103 cells (p < .01). TMPH inhibited
both basal and gastrin driven histamine secretion with a maximal effect (34 per-
cent) (1.78 ±0.08 nmol/103 cells) and anIC50 of> 5x10-7 M. H1 receptorantag-
onism did not alter histamine secretion alone or in combination with gastrin.
Neither H receptor stimulation nor antagonism had any effect on histamine
secretion alone orincombination withgastrin. Gastrin-induced histamine secre-
tion was dose-dependently inhibited by imetit (H3 agonist) with a maximal
effect (2.4 ± 0.6 nmoII103 cells) (p < .05) and an IC50 of 10-9 M. Conversely,
Thioperamide (H3 antagonist) dose-dependently augmented gastrin-stimulated
histamine secretion with a maximum effect (5.7 ± 0.5 nmolI03 cells) (p < .05)
at 10-8 M and anEC50 of7xI0-10 M.
Conclusion: These data areconsistent with thepresence ofan H3 receptoron the
ECL cell which modulates gastrin-stimulated histamine secretion. Our observa-
tions support the proposal that a histamine-mediated short-loop autocrine regu-
latory mechanism ofECL cell secretion exists.
INTRODUCTION
Histamine is presentin the stomach inhigherconcentrations than in any otherbody tis-
sue. Its major source is the enterochromaffin-like (ECL)b cell ofthe oxyntic mucosa [1, 2].
The ECL cell has been identified as the principle regulator ofacid secretion, and thus plays
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a critical role in gastric physiology [3-5]. Regulation ofhistamine secretion is complex and
is primarily by gastrin activation ofthe ECL cell gastrin/CCK-B receptor, which stimulates
both histamine synthesis and DNA synthesis [2]. Increased plasma gastrin levels result in
ECL cell proliferation and increased histamine secretion [6]. The effects ofelevated local
histamine concentrations are unknown but of considerable relevance since histamine has
protean biological effects including a substantial role in the genesis ofinflammation and as
a known mitogen in a number ofcell systems [3].
The specific physiological effects ofhistamine appear to bemediated by at leastthree
subclasses ofcell surface histamine receptors: H1 receptors were initially identified in the
brain and noted to regulate the postsynaptic response to histamine [7]. The second sub-
type, the H2 receptor, and the identification of its relevance to gastric parietal cell secre-
tion, revolutionized the therapy of acid-peptic disease [8]. Arrang et al. in 1983 demon-
strated feed-backinhibition ofhistamine synthesis andrelease inhistaminergic neurons in
the brain through a third histamine receptor subtype [9]. The subsequent development of
selective H3 receptoragonists and antagonists has led to the identification ofthis receptor
subtype on a number of peripheral tissues including perivascular nerve terminals, the
enteric gangliaofthe ileum and the lung [10-13]. In vivo, H3 receptorstimulation has been
reported to inhibit gastrin, bombesin, 2-deoxyglucose and meal-stimulated acid secretion
in cats and dogs [14-17]. Additional studies have noted that H3 receptor stimulation
inhibits histamine release from the rat stomach [18], rabbit gastric gland [19], rabbit gas-
tric mucosal cells [20] and isolated rat ECL cells [2].
The possibility that histamine could autoregulate its own synthesis and release was
initially postulated in 1964 by Kahlson. He proposed that the labile histamine forming
capacity observed in the gastric mucosa ofcats, mice and frogs could be explained ifthere
were to exist a feedback control of histamine forming capacity by the histamine content
of the mucosa [21]. The subsequent identification of the ECL cell as a major source of
mucosal histamineprovided supportfor the erroneous suggestion thatthe ECLcell, via an
H2-receptor, might negatively mediate its histamine secretory response to gastrin [22].
This postulate could not be adequately tested in an intact stomach ormucosal preparation.
The recent development of a preparation of pure, isolated ECL cells has allowed
exploration of the regulatory mechanisms of acid secretion, histamine release and prolif-
eration that have heretofore been impossible [2]. Since the ECL cell is the major physio-
logic site ofhistamine synthesis and secretion in the stomach, we have examined the pro-
posal that its secretory function may be modulated by histamine autoreceptors. The pur-
pose ofthis study was to investigate the effects ofhistamine and histamine subtype recep-
tor ligands on ECL cell secretory function.
MATERLALS AND METHODS
Human gastrin-17 and dimaprit was purchased from Research Plus, Inc., Bayonne,
New Jersey. Terfenadine was obtained from Sigma Chemical Co., St. Louis, Missouri;
Cimetidine and Loxtidine were kind gifts from Glaxo, UK.; TMPH was a kind gift ofW.
Schunack, Berlin, Germany; imetit and thioperamide were kind gifts from J.C. Schwarz,
Paris, France. Nycodenz was fromAccurate Chemical & Scientific Corp., Westbury, New
York. Pronase E was purchased from Boehringer-Mannheim, Indianapolis, Indiana.
HistamineEIA kit was obtained from ImmunotechInternational,AMAC, Inc.,Westbrook,
Maine. Forty-eight well collagen-I-coated plates were from Becton-Dickinson, Bedford,
Massachussets.All otherreagents were obtained from thehighestquality source available.
Cell isolation
Rat ECL cells were prepared by a modification of the method of Prinz [2]. The
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Foreach condition studied, the stomachs from four animals (n = 1) were excised and evert-
ed to make mucosal-side-out sacs. Following a thorough rinse with PBS, pronase E was
injected into the stomach sacs. The stomachs were then incubated in an oxygenated calci-
um-free medium containing 1 mM EDTA for 30 min, followed by a 10-min incubation in
a calcium-respiration medium. The stomachs were then transferred back to calcium-free-
EDTA medium for an additional 30-min incubation. The mucosal cells were harvested by
gentle stirring for 10 min in calcium-respiration medium and collected by centrifugation
(100 X g, 5 min). This crude cell fraction was subjected to counterflow elutriation (JE-6
rotor, Beckman Instruments). Small cells with diameter of 8 to 10 pm were collected at
2,000 rpm and a flow rate of20 mlmin. This fraction was subsequently layered on a step
Nycodenz density gradient and centrifuged at 1100 rpm for 8 min. The ECL cell enriched
fraction was collected at the interface ofdensity 1.040 g/ml.
Cell viability
Cell viability was demonstrated by trypan blue exclusion using light microscopy.
Quantitation was performed by counting the number ofcells that excluded trypan blue (>
95 percent) and dividing by the total number ofcells in five randomly selected fields at 40
X magnification.
Cell culture
Isolated cells were washed in culture medium (Dulbecco's Minimal Essential
MediumIF12 with two percent bovine serum albumen, pH 7.4) by centrifugation and
resuspension. Thereafter, cells were resuspended in growth medium (culture medium plus
two percent FCS, ITS 0.5 mg/lOO ml, hydrocortisone 10 nM, gentamicin 0.1 mg/100 ml)
at a final concentration of 106 cells/ml, and 200 ul added to each well of a 48-well
Collagen-I plate. The cells were cultured overnight at 370C under standard conditions.
Cell secretion
Stimulation ofHistamine Secretion: After 24 hr, the growth medium was removed and
replaced with 200 ul ofculture medium. After the addition ofeither culture medium alone
(control) or secretagogues at one percent of the final incubation volume, the cells were
incubated at 370C for 60 min. Then, halfofthe medium was removed from each well and
centrifuged at 15,000 X g for 30 sec. Supernatant was diluted 1:10 and stored at -200C for
measurement of histamine content by specific EIA.
Histamine EIA: The basis of this assay is competition between the histamine in the
sample and the enzyme conjugate histamine acetylcholinesterase, used as a tracer, for
binding to monoclonal antibody coated tubes using a commercially available kit. Bound
enzymatic activity is measured by the addition of a chromogen substrate, and the intensi-
ty of colour development is measured by a spectrophotometer (microplate reader model
EL 312e, Biotek Instruments, Vermont). Sample histamine concentrations are calculated
from a negative spline-curve. This assay has been adjusted (dilution and non-specific
activity) for use over a range from 50 to 0.5 nmol/103 cells and is sensitive (0.2 nmol
detection level) and specific (interassay variation 9.4 percent, intra-assay variation 8.0 per-
cent). Histamine levels were expressed as nmol/103 cells. All agents were tested to ensure
no cross-reactivity in the assay.
Statistical analyses
Statistics was calculated using the Excel 4.0 (Macintosh) program. Results are
expressed as mean ± SE. Statistical significance was evaluated using eitherANOVA or the
two tailed Student's test for paired and unpaired values as appropriate, with a probability
11Kidd et al.: Autoregulation ofECL cell histamine secretion
of p < .05 representing significance. The number ofECL cell preparations is represented
by "n" (four animals per preparation).
RESULTS
A 90 to 95 percent pure preparation of ECL cells was developed from rat fundic
mucosa as determined by chromogranin and histamine immunofluorescence, markers for
ECL cells. Cell viability was > 95 percent as demonstrated by trypan blue exclusion.
Secretion
Gastrin: Basal histamine secretion was 2.7 ± 0.14 nmol/103 cells. A dose response to
gastrin was evident (EC50 1 x 10-10 M). Maximum stimulation (4.6 ± 0.4 nmol/103 cells)
was noted at 10-8 M (Figure 1).
Histamine: No accurate estimate ofsecretion was possible since stimulation with his-
tamine interfered with the histamine assay.
Histamine-i receptor ligands
TMPH: The H1 receptor agonist (10-10_10-6 M) alone inhibited basal histamine
secretion (34 percent) at 10-6 M, and an estimated IC50 of > 5 x 10-7 M (Figure 2).
Gastrin-stimulated (10 nM) histamine secretion was inhibited in a similar fashion (Figure
3). TMPH in a model ofguinea pig ileal contraction was originally characterized with an
EC50 of -1.5 x 10-7 M [23]. In addition, this molecule has been demonstrated to have a
substantial cross reactivity with the H3 receptor subtype (EC50 _10-5 M) [23]. It is diffi-
cult to interpret the pharmacological effect of TMPH in our model because of the pres-
ence of substantial amounts of endogenous histamine which has a similar affinity (2 x
10-7 M) and efficacy (78 percentcompared withTMPH) for the H1 receptor subtype. The
high concentration required to inhibit secretion in our model suggests that this may be a
non-pharmacological event orelse represent cross-selectivity with other histamine recep-
tor subtypes.
Terfenadine: The H1 receptor antagonist terfenadine (10-10 to 10-6 M) had no effect
on basal or gastrin-stimulated (10 nM) histamine secretion.
In a separate set ofstudies (data not shown) we have shown that terfenadine at 1 nM
inhibits gastrin-stimulated DNA synthesis and that this effect is completely reversed by
TMPH in adose dependent fashion with an estimatedEC50 value of 10-9 M. It would thus
seem more likely that the H1 receptor exhibits a proliferative rather than a secretory role.
Histamine-2 receptor ligands
Dimaprit: The H2 receptor agonist dimaprit (10-10 to 10-6 M) did not alter basal or
gastrin-stimulated (10 nM) histamine secretion.
Cimetidine and loxtidine: Neither the competitive H2 receptor antagonist cimetidine
(10-10 to 10-6 M) nor the irreversible H2 receptor antagonist loxtidine (10-10 to 10-6 M)
altered basal or gastrin-stimulated (10 nM) histamine secretion.
Histamine has been demonstrated to have a similar affinity and efficacy as these
agents for the H2 receptor subtype [7]. The observation that the ECL cell does notrespond
to these agents suggests that underequivalent conditions, histamine has no directeffect on
the ECL cell. Since the parietal cell expresses the H2 receptor subtype, it is possible that
the ECL cell does not exhibit the H2 receptor.
Histamine-3 receptor ligands
Imetit: The H3 receptor agonist imetit (10-10 to 10-6 M) did not alter basal histamine
secretion. However, pretreatment with imetit inhibited a sub-maximal dose of gastrin-
stimulated (1 nM) histamine secretion (38 percent) at 10-6 M, and an IC50 of -10-9 M
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Figure 1. The gastrin dose response for ECL cell histamine secretion. Control levels were 2.7 +
0.14 nmoles/103 cells. Gastrin-stimulated histamine release with an estimated EC o of Ix1O-10 M
(3.65 ± 0.18 nmoles/103 cells, p < .01 vs. control) and an ECmax of 10-8 M (4.6 + 0.37 nmoles/103
cells, p < .005 vs. control) (n = 7).
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Figure 2. The inhibitory effect of the H receptor agonist, TMPH, on basal histamine secre-
tion. Control levels are 2.5 ± 0.27 nmolesh03 cells. TMPH dose-dependently inhibited histamine
release with an IC50 of > 5x10-7 M and a maximal effect at 10-6 M (1.94 ± 0.34 nmoles/103 cells).
Maximum inhibition was 34 percent (p < .05 vs. control) (n = 3).
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Figure 3. The inhibtory effect ofthe H1 receptor agonist, TMPH, on gastrin-stimulated hista-
mine secretion. Gastrin levels are 3.8 + 0.4 nmoles/103 cells. TMPH inhibited histamine release
with an estimated IC50 of 5x108 M. Maximum inhibition was approximately 26 percent (p = .05 vs.
gastrin) (n = 3).
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Figure 4.Theinhibitory effectofthe H3 receptoragonist,imetit, on a sub-maximal dose ofgas-
trin-stimulated (10-9 M) histamine secretion (3.9 ± 0.4 nmoles/103 cells). Control levels are 3.0
± 0.2 nmoles/103 cells. Imetit dose-dependently inhibited histamine release with an IC50 of 10-9 M.
Maximum inhibition was 38 percent (2.4 ± 0.6 nmoles/103 cells) (p < .05 vs. gastrin) (n = 3).
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Figure 5. The effect ofthe H3 receptor antagonist, Thioperamide, on gastrin-stimulated (10-9
M) histamine secretion (3.9 *0.4nmoles/103 cells). Control levels are 2.9 +0.18 nmoles/103 cells.
Thioperamide dose-dependently augmented gastrin driven release with an EC50 of7xlO-10 M and
an ECM X of 10-8 M (5.7 ± 0.5 nmoles/103 cells). The maximal augmentation was 146 percent vs.
gastrin rp < .05) (n = 3)
(Figure 4). The higher dosage of imetit was not used due to the concern of non-specific
effects.
Thioperamide: The H3 receptor antagonist thioperamide (10-10 to 10-6 M) did not
alter basal histamine secretion. However, pretreatment with thioperamide augmented a
sub-maximal dose ofgastrin-stimulated (1 nM) histamine secretion with a maximal effect
(146 percent) at 10-8 M and an EC50 of 7 x 10-10 M (Figure 5). This value is consistent
with the reported affinity ofthioperamide for the H3 receptor subtype (4 x 10-9 M) [10].
Thioperamide then imetit, then gastrin: To determine the specificity of the effect of
H3 receptor on gastrin-stimulated histamine secretion, cells were pretreated with H3
receptor antagonist thioperamide (10 nM) followed by the H3 receptor agonist imetit
(10-10 to 10-6 M) and then stimulated with gastrin (1 nM). This abolished the previous-
ly observed imetit mediated inhibition of gastrin-stimulated histamine secretion (data
not shown).
Histamine has been demonstrated to have a substantially lower affinity (18-fold less)
but a similar efficacy for the H3 receptor subtype compared with the specific H3 receptor
agents [9]. The low concentrations ofH3 agents required to alter histamine secretion sup-
port the presence of an H3 receptor on the ECL cell. It is probable that histamine, albeit
at a higher concentration, has a similar effect. Pharmacological manipulation of the H3
receptor with highly specific agents, therefore, demonstrates unequivocally that receptor
activation of the ECL cell results in inhibition ofhistamine release.Kidd et al.: Autoregulation ofECL cell histamine secretion
DISCUSSION
Although the role ofhistamine in normal physiology has been widely investigated, its
biological relevance is incompletely understood. Nevertheless, compounds that selective-
ly antagonize the actions of histamine at these specific cell surface receptors are of con-
siderable clinical utility. Histamine has been determined to exert its complex physiologic
and pathologic effects through interaction with atleast three receptor subtypes (H1, H2 and
H3) [7, 24] identified on numerous different cell systems including neural and gastroin-
testinal. Message transduction via the H1 receptor has been shown to involve alterations in
calcium homeostasis and increased production of inositol phosphate, while H2 receptors
are reported to act through elevation of cAMP [3]. The mode of action ofH3 receptors is
unknown but it is thought to be negatively coupled to phosphatidylinositol turnover [25].
A role for the H1 receptor in the regulation of gastric histamine secretion is both
unclear and controversial but has been suggested from the results of experiments with
anesthetised dogs with gastric fistulas. In these experiments, infusion of an H1-receptor
agonist (2', 2-pyridyl ethylamine) had no effect on dimaprit stimulated acid secretion [26].
However, infusion of the specific receptor antagonist, hydroxyzine dihydrochloride,
enhanced both histamine and dimaprit stimulated gastric acid secretion. Removal of an
autoinhibitory effect of histamine on histamine secretion from the ECL cell by an H1
receptor antagonist might explain these data but the precise interpretation of such studies
in intact animals has been difficult. The presence ofH1 receptors in the gastric mucosa has
been suggested by binding studies. In preliminary studies, [3H]Mepyramine binding in
gastric tissue samples from the African rodent Praomys natalensis indicated low levels of
H1-receptors in both antrum and fundus, -15 fmol/mg protein [27]. The further possibili-
ty that the receptor sites were present on ECL cells was supported by an increased degree
of binding in ECL cells isolated from fundic ECL carcinoid tumors (Schwartz and
Modlin, unpublished data).
In order to evaluate the role oftheHI receptordirectly, we used the agents TMPH and
terfenadine. TMPH is a 3-trifluoromethyl derivative of histamine, which is a specific H1
receptor agonist, and has been reported to be similarly potent to histamine in the guinea
pig ileum assay [23]. Terfenadine is a selective, slow-associating H1 receptor antagonist,
which forms a stable complex and has been demonstrated to have a IC50 of 0.2 uM for
ileal H1 receptors [28]. In an isolated purified preparation of ECL cells, the H1 receptor
agonist, TMPH (at high dosage), significantly inhibited both basal and a maximal dose of
gastrin-stimulated (10 nM) histamine secretion with IC50 > 0.5 uM. However, the H1
receptor antagonist, terfenadine, had no effect on either basal or gastrin driven histamine
release. Although these results suggest that ECL cell histamine secretion can be modulat-
ed by the H1 receptor subtype, the high concentrations required are of concern. In addi-
tion, since the H1 receptor clearly modulates proliferation both in vivo and in vitro, it
seems more likely that the observed effects reflect a degree of non-selectivity or cross-
reactivity with the H3 receptor subtype generated by high dosages of a pharmacological
compound.
The histamine-2 receptor has been identified on the parietal cell, and pharmacological
blockade has proved efficacious in the treatment ofpatients with acid relateddisorders. The
presence of an H2 receptor and evidence for an H2 mediated feed-back inhibition on ECL
cell histamine release was initially proposed in 1978 [22]. Histamine has been demonstrat-
ed both to inhibit HDC activity in vivo and to decrease the half-life of the enzyme [22].
Intravenous infusion of histamine in rats treated with the H2 receptor blocker, metiamide,
resulted in a significantly reduced suppression of HDC activity and in addition, pentagas-
trin-induced HDC activity in the fundic mucosa was significantly increased. The effect of
these agents on histamine secretion was not determined. Based on this information,
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Hikanson postulated that H2 receptor blockade might be mediated at the level ofthe ECL
cell rather than the parietal cell. Our studies, utilizing a purified population of ECL cells,
demonstrated that the specific H2 receptor agonist, dimaprit, had no effect on either basal
or gastrin-stimulated histamine secretion. Similarly, the specific H2 antagonists, cimetidine
and loxtidine, had no effect on histamine secretion. In separate studies, we have reported
that neither H2 receptor activation nor blockade altered basal or gastrin-stimulated hista-
mine secretion or DNA synthesis [27], suggesting that there is no evidence for arole ofthe
H2 receptor subtype in the regulation ofthe ECL cell.
The histamine-3 receptor was initially described in the brain, where it inhibits hista-
mine synthesis and release [29]. H3 receptors were subsequently identified in the enteric
ganglia ofthe gastrointestinal tract, and evidence provided to support a role in the modu-
lation of cholinergic neurotransmission [30]. More recently, it has been reported that this
class of histamine receptor subtype is involved in the control of gastric acid secretion.
Evidence for the existence of a gastric H3 receptor was initially derived from in vivo stud-
ies utilizing fistula cats [14, 31]. Acid secretion stimulated by meal or pentagastrin was
potently and dose-dependently inhibited by the specific H3 agonist, R-MHA. This activa-
tion could be reversed by the specific antagonist, thioperamide. Similar findings were
observed in a denervated Heidenhain pouch, suggesting that extrinsic cholinergic vagal
nerves were not involved in this process. In addition, in the isolated rat stomach, R-MHA
inhibited both basal and gastrin-stimulated vascular histamine release in a ranitidine-
insensitive manner [18], suggesting direct modulation ofhistamine receptors on histamine
secreting cells. Indeed to date, no evidence exists for the presence of H3 receptors on the
parietal cell. Furthermore, histamine inhibited HDC activity in isolated rabbit mucosal
cell preparations can be augmented by R-MHA and reversed by thioperamide [20].
Histamine thus appears to inhibit its own synthesis via H3 autoreceptors within the gastric
mucosa. Evidence for the functional presence of an H3 receptor in isolated rat ECL cells
was reported by Prinz et al. [2]. Their results indicated a specific inhibition of maximal
CCK-8 (10-8 M) stimulated histamine release by R-MHA with a maximum effect at 10-6
M. In addition, the effects of a sub-maximal dose (10-10 M) ofCCK-8 could be augment-
ed by thioperamide maximally at 10-8 M. In order to evaluate the role of the H3 receptor
directly, we used the agents imetit and thioperamide. Imetit is a potent, selective H3 recep-
tor agonist, which is equipotent to R-MHA. Both agents exhibit -3x the inhibitory effect
of histamine for [3H]-histamine release from rat cortical slices [29]. Thioperamide is a
competitive H3 receptor antagonist with little cross-reactivity for either the H1 or H2
receptors [10]. Using similarly isolated cells that were allowed to recover following
overnight culture, we have demonstrated that imetit specifically inhibits a submaximal
dose ofgastrin (10-9 M) driven histamine secretion with an IC50 of 10-9 M and a maximal
degree ofinhibition of-40percent. Thioperamide dose-dependently augmented histamine
secretion with an EC50 of7x10-10 M. Maximal augmentation (-50 percent) occurred at a
dose of 10-8 M. These values are consistent with previous in vivo and in vitro studies. The
specificity of this effect was demonstrated by pretreatment of the ECL cells with the
receptor antagonist (thioperamide), which abolished the inhibitory effect ofImetit on gas-
trin driven histamine secretion. The demonstration of both incomplete attenuation and
augmentation of histamine release by these agents suggests that gastrin-mediated hista-
mine release may be effectively modulated or fine tuned by histamine 3 receptor subtype
activation.
Since areceptor may presentbinding sites with differing affinity states for ahormone,
and we have previously demonstrated that histamine effectively modulates ECL cell pro-
liferation in vitro [27], it is probable that the H3 receptor functions in different affinity
states which variously alter DNA synthesis or modify histamine secretion. Both the gas-
trin/CCK-B receptor and the CCK-A receptor are known to exhibit such phenomena [32].
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In the ECL, cell the EC50 for gastrin mediated ECL cell DNA synthesis is an order of
magnitude less than for histamine secretion [33, 34]. Both high and low affinity states for
H3 receptors have been demonstrated using radiolabelling of cerebral membranes [29].
High affinity binding has been proposed to modulate HDC activity, while low affinity
binding is thought to regulate histamine secretion. Low levels of basal histamine release
are postulated to down-regulate histamine synthesis, while high concentrations of hista-
mine consequent upon stimulated secretion inhibit histamine release [20]. Our results
demonstrate that H3 receptor activation results in substantial inhibition of histamine
release. It is probable that histamine released by gastrin would remain in very close prox-
imity to the ECL cell and result in accumulation of histamine at a high local concentra-
tion. Under these circumstances, it is feasible that histamine induces a local feedback
inhibitory effect via the H3 receptor and thus downregulates the initial systemic hormon-
al signal. It is, therefore, possible that in the gastric mucosa a component of the physio-
logic function of histamine receptor subtypes may be to exert tonic inhibition of acid
secretion via regulation ofECL cell histamine secretion and synthesis.
The utility ofpharmacological compounds to define specific receptor subtype activi-
ty is limited by the specificity of such agents. Thus, it cannot be excluded that the
observed effects of TMPH at high dosage reflect an effect on the H3 receptor.
Nevertheless, the effect ofthe various histamine receptor subtype probes clearly indicates
a role for the histamine receptor subtype 3 in the modulation of histamine secretion. The
validity ofthis proposal is further supported by the autoradiographic demonstration ofthe
H3 receptor on the isolated ECL cell [27]. Given the critical position of the ECL cell in
the regulation of acid secretion, the existence of a histamine-activated autoregulatory
secretory mechanism is of considerable physiological and possibly clinical relevance.
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